Journal
EXPERT REVIEW OF HEMATOLOGY
Volume 6, Issue 1, Pages 49-58Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/EHM.12.69
Keywords
bone marrow fibrosis; essential thrombocythemia; interferon; JAK2 mutation; myeloproliferative disorders; myeloproliferative neoplasms; Philadelphia-negative neoplasms; polycythemia vera; primary myelofibrosis
Categories
Funding
- William and Judy Higgins trust
- Johns Family of the Cancer Research and Treatment Fund, Inc., NY, USA
Ask authors/readers for more resources
Recombinant IFN-alpha (rIFN-alpha) induces complete hematologic remissions in patients with myeloproliferative neoplasms (MPNs), but its use has been limited by side effects owing to the relatively high doses used. Now, low-dose rIFN-alpha is stressed, starting relatively early in the course of the MPNs. In polycythemia vera, this has resulted in a significant clinical, hematologic, morphologic and molecular response manifested by reduction in the JAK2(V617F) allele burden, sustained even after discontinuation of recombinant IFN. In essential thrombocythemia, platelet count reduction is prompt and durable without treatment for varying periods. In hypercellular primary myelofibrosis, rIFN-alpha has restored normal blood counts, reduced splenomegaly and induced morphologic marrow remissions. This article highlights our current use of rIFN-alpha in MPNs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available